Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma-Reference-Cited by-同舟云学术

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma

Published:2023-12 Issue:6 Volume:8 Page:102038
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Blay J.Y.^ORCID,Cropet C.^ORCID,Mansard S.,Loriot Y.,De La Fouchardière C.,Haroche J.,Topart D.,Tougeron D.^ORCID,You B.,Italiano A.,Le Brun-Ly V.,Ferrero J.M.,Penel N.,Fabbro M.,Troussard X.,Malka D.^ORCID,Ray-Coquard I.,Leboulleux S.,Fléchon A.,Maubec E.,Charles J.,Dalle S.,Taieb S.,Garcia G.C.T.E.^ORCID,Mandache A.M.,Colignon N.,Gavrel M.,Nowak F.,Hoog Labouret N.,Mahier Aït Oukhatar C.,Gomez-Roca C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference31 articles.

1. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

2. Vemurafenib: the first drug approved for BRAF-mutant cancer;Bollag;Nat Rev Drug Discov,2012

3. BRAFV600E mutation-specific antibody: a review;Ritterhouse;Semin Diagn Pathol,2015

4. The multifaceted anti-cancer effects of BRAF-inhibitors;Croce;Oncotarget,2019

5. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N Engl J Med,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Understanding and Management of Erdheim-Chester Disease;Life Sciences;2024-07

2. A critical review of RAF inhibitors in BRAF-mutated glioma treatment;Pharmacogenomics;2024-05-02

3. Characterization of BRAF^Thr599dup Mutation as a Targetable Driver Mutation Identified in Lung Adenocarcinoma by Comprehensive Genomic Profiling;JCO Precision Oncology;2024-04